PURPOSE: To elucidate the reasons for conflicting results regarding the prognostic significance of tumor location in upper tract urothelial carcinoma (UTUC), we analyzed the stage-specific impact of tumor location on oncological outcomes following radical nephroureterectomy (RNU). METHODS: Data from 392 patients who underwent RNU with curative intent between 1991 and 2010 were reviewed. Prognostic impact of tumor location and various clinicopathological factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Kaplan-Meier and Cox regression analyses at each pathological stage. Tumor location was classified as renal pelvis or ureter, and pT3 tumors were further stratified as invading the renal parenchyma or peripelvic or periureteral fat. RESULTS: In stage-specific analysis, tumor location did not have prognostic significance in patients with ≤pT2 tumors, whereas RFS and CSS rates were significantly lower in patients with pT3 ureteral tumors than renal pelvic tumors. Subgroup analysis showed that RFS and CSS rates were significantly higher for pT3 tumors invading the renal parenchyma than the peripelvic or periureteral fat. On multivariate analysis in pT3 tumors adjusting other clinicopathological parameters, tumor location remained significant predictors for both RFS and CSS. Compared with tumors invading renal parenchyma, tumors invading peripelvic fat or periureteral fat were associated with about 3.5 times higher risk for cancer-specific mortality (p < 0.05). CONCLUSIONS: Location-dependent survival difference exists only in patients with pT3 UTUC. Conflicting institutional results regarding tumor location in UTUC may be due to difference in the proportions of parenchymal versus peripelvic fat invasion in pT3 pelvic tumors.
PURPOSE: To elucidate the reasons for conflicting results regarding the prognostic significance of tumor location in upper tract urothelial carcinoma (UTUC), we analyzed the stage-specific impact of tumor location on oncological outcomes following radical nephroureterectomy (RNU). METHODS: Data from 392 patients who underwent RNU with curative intent between 1991 and 2010 were reviewed. Prognostic impact of tumor location and various clinicopathological factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) was evaluated using Kaplan-Meier and Cox regression analyses at each pathological stage. Tumor location was classified as renal pelvis or ureter, and pT3tumors were further stratified as invading the renal parenchyma or peripelvic or periureteral fat. RESULTS: In stage-specific analysis, tumor location did not have prognostic significance in patients with ≤pT2 tumors, whereas RFS and CSS rates were significantly lower in patients with pT3ureteral tumors than renal pelvic tumors. Subgroup analysis showed that RFS and CSS rates were significantly higher for pT3tumors invading the renal parenchyma than the peripelvic or periureteral fat. On multivariate analysis in pT3tumors adjusting other clinicopathological parameters, tumor location remained significant predictors for both RFS and CSS. Compared with tumors invading renal parenchyma, tumors invading peripelvic fat or periureteral fat were associated with about 3.5 times higher risk for cancer-specific mortality (p < 0.05). CONCLUSIONS: Location-dependent survival difference exists only in patients with pT3 UTUC. Conflicting institutional results regarding tumor location in UTUC may be due to difference in the proportions of parenchymal versus peripelvic fat invasion in pT3pelvic tumors.
Authors: Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner Journal: Eur Urol Date: 2012-02-23 Impact factor: 20.096
Authors: Michael Rink; Behfar Ehdaie; Eugene K Cha; David A Green; Pierre I Karakiewicz; Marko Babjuk; Vitaly Margulis; Jay D Raman; Robert S Svatek; Harun Fajkovic; Richard K Lee; Giacomo Novara; Jens Hansen; Siamak Daneshmand; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Armin Pycha; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-02-15 Impact factor: 20.096
Authors: Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara Journal: World J Urol Date: 2011-01-20 Impact factor: 4.226
Authors: James W F Catto; Abdel-Rahmene Azzouzi; Ishtiaq Rehman; Kenneth M Feeley; Simon S Cross; Najla Amira; Gaelle Fromont; Mathilde Sibony; Oliver Cussenot; Mark Meuth; Freddie C Hamdy Journal: J Clin Oncol Date: 2005-03-07 Impact factor: 44.544
Authors: Mesut Remzi; Andrea Haitel; Vitaly Margulis; Pierre Karakiewicz; Pierre Karakiewizc; Francesco Montorsi; Eiji Kikuchi; Richard Zigeuner; Alon Weizer; Christian Bolenz; Karim Bensalah; Nazareno Suardi; Jay D Raman; Yair Lotan; Matthias Waldert; Casey K Ng; Mario Fernández; Theresa M Koppie; Philipp Ströbel; Wareef Kabbani; Masaru Murai; Cord Langner; Marco Roscigno; Jeffrey Wheat; Charles C Guo; Christopher G Wood; Shahrokh F Shariat Journal: BJU Int Date: 2008-10-16 Impact factor: 5.588
Authors: Giacomo Novara; Vincenzo De Marco; Fedra Gottardo; Orietta Dalpiaz; Vianney Bouygues; Antonio Galfano; Guido Martignoni; Jean Jacques Patard; Walter Artibani; Vincenzo Ficarra Journal: Cancer Date: 2007-10-15 Impact factor: 6.860
Authors: D R Yates; V Hupertan; P Colin; A Ouzzane; A Descazeaud; J A Long; G Pignot; S Crouzet; F Rozet; Y Neuzillet; M Soulie; T Bodin; A Valeri; O Cussenot; M Rouprêt Journal: Br J Cancer Date: 2012-02-28 Impact factor: 7.640
Authors: Tzu Shuang Chen; Yen Ta Chen; Hung Jen Wang; Po Hui Chiang; Wen Chou Yang; Wei Ching Lee; Yao Chi Chuang; Yuan Tso Cheng; Chih Hsiung Kang; Wei Chia Lee; Chien Hsu Chen; Yuan Chi Shen; Yi Yang Liu; Hui Ying Liu; Yin Lun Chang; Yu Li Su; Chun Chieh Huang; Hao Lun Luo Journal: Front Oncol Date: 2022-03-15 Impact factor: 6.244